Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trialBhagirathbhai Dholaria, Olalekan O. Oluwole, Shakthi Bhaskar et al.|Bone Marrow Transplantation|2025Cited by 9
Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical GuideKian J. Rahbari, Bhagirathbhai Dholaria, Raul del Toro Mijares et al.|JCO Oncology Practice|2025Cited by 3
Flat dose intravenous immunoglobulin (IVIG) for primary infection prophylaxis after CAR-T for B-cell non-Hodgkin lymphoma (B-NHL).Spencer Lessans, Vivek Patel, Morgan L. Zenner et al.|Journal of Clinical Oncology|2024Cited by 2
Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt ExperienceNaimisha Marneni, Muhamed Baljević, Bhagirathbhai Dholaria et al.|Blood|2023Cited by 2
Long-term outcomes after cardiac transplantation in AL amyloidosis.Spencer Lessans, Lynn Punnoose, Vivek Patel et al.|Journal of Clinical Oncology|2024Cited by 0